[Thrombocyte transfusion: clinical aspects, follow-up and complications]
- PMID: 1921239
- PMCID: PMC7095859
- DOI: 10.1007/BF01647409
[Thrombocyte transfusion: clinical aspects, follow-up and complications]
Abstract
Thrombocytopenia is the most common cause of bleeding tendency, and, if due to impaired platelet production, is best treated by platelet transfusions. Prophylactic transfusions for asymptomatic patients should be considered if platelet count is below 20,000/microliters. However, if bleeding occurs or surgery is inevitable, platelet count should be maintained above 50,000/microliters. The benefit of platelet transfusions has to be balanced against risks like fever, infections and haemolysis. The effectiveness of platelet transfusions should be examined after 1 and 24 hrs by measuring the corrected count increment (CCI). Not only alloimmunization is a reason for unsatisfactory platelet increments. A poor CCI can also be due to fever, sepsis, hepato-splenomegaly or special drugs, which must be taken into account when assessing the demand for platelet transfusions.
Similar articles
-
[Ex-vivo bleeding time as a control for platelet transfusion].Beitr Infusionsther Transfusionsmed. 1994;32:459-66. Beitr Infusionsther Transfusionsmed. 1994. PMID: 9480143 Clinical Trial. German.
-
[Thrombocyte substitution, 2: Thrombocyte preparations and determining the effectiveness of thrombocyte transfusion].Z Gesamte Inn Med. 1986 Dec 1;41(23):647-51. Z Gesamte Inn Med. 1986. PMID: 3577256 German.
-
Predictive value of lymphocytotoxic test and platelet aggregometry for the effect of transfused platelet concentrates.Haematologia (Budap). 1981 Dec;14(4):375-81. Haematologia (Budap). 1981. PMID: 7344974
-
Neonatal Platelet Transfusions and Future Areas of Research.Transfus Med Rev. 2016 Oct;30(4):183-8. doi: 10.1016/j.tmrv.2016.05.009. Epub 2016 May 27. Transfus Med Rev. 2016. PMID: 27282660 Review.
-
Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.Clin Chest Med. 2003 Dec;24(4):607-22. doi: 10.1016/s0272-5231(03)00100-x. Clin Chest Med. 2003. PMID: 14710693 Review.
Cited by
-
[Conventional vs pathogen-inactivated platelet concentrates for the treatment of perioperative coagulopathy. A prospective cohort study].Chirurg. 2011 Apr;82(4):348-58. doi: 10.1007/s00104-010-2023-2. Chirurg. 2011. PMID: 21249326 Clinical Trial. German.
References
-
- Alter HJ, Purcell RH, Holland PV, et al. Donor transaminase and recipient hepatitis. Impact on blood transfusion services. J Am Med Assoc. 1981;246:630–634. - PubMed
-
- Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989;231:1494–1500. - PubMed
-
- Andrews AT, Zmijewski CM, Bowman HS, et al. Transfusion reaction with pulmonary infiltration associated with HLA specific leukocyte antibodies. Am J Clin Pathol. 1976;66:483–487. - PubMed
-
- Baldwin ML, Ness PM, Scott D, et al. Alloimmunization to D-antigen and HLA in D-negative immunosuppressed oncology patients. Transfusion. 1988;28:330–333. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical